Current concepts of tumor-infiltrating lymphocytes in human malignancies

Journal of Reproductive Immunology

Volumn 67, Issue 1-2, 2005, Pages 35-50

  Chiou, Shin Heng ^a   Sheu, Bor Ching ^a   Chang, Wen Chun ^a   Huang, Su Cheng ^a   Hong Nerng, Ho ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Human malignancies; Pregnancy; Tumor immunology; Tumor infiltrating lymphocytes

Indexed keywords

FAS LIGAND; INTERLEUKIN 2; MATRIX METALLOPROTEINASE;

CELL MEDIATED CYTOTOXICITY; ENZYME ACTIVITY; HOST RESISTANCE; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 26244441316     PISSN: 01650378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jri.2005.06.002     Document Type: Short Survey

References (127)

1. S. Agrawal, J. Marquet, M.H. Delfau-Larue, C. Copie-Bergman, H. Jouault, F. Reyes, A. Bensussan, and J.P. Farcet CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs J. Clin. Invest. 102 1998 1715 1723
2. A.N. Akbar, N. Borthwick, M. Salmon, W. Gombert, M. Bofill, N. Shamsadeen, D. Pilling, S. Pett, J.E. Grundy, and G. Janossy The significance of low bcl-2 expression by CD45RO T cells in normal individuals and patients with acute viral infections. The role of apoptosis in T cell memory J. Exp. Med. 178 1993 427 438
3. J.P. Alexander, S. Kudoh, K.A. Melsop, T.A. Hamilton, M.G. Edinger, R.R. Tubbs, D. Sica, L. Tuason, E. Klein, R.M. Bukowski, and J. Finke T cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin-2 and express interleukin-2 receptors Cancer Res. 53 1993 1380 1387
4. J. Allison, H.M. Georgiou, A. Strasser, and D.L. Vaux Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts Proc. Natl. Acad. Sci. U.S.A. 94 1997 3943 3947
5. V.R. Aluvihare, M. Kallikourdis, and A.G. Betz Regulatory T cells mediate maternal tolerance to the fetus Nat. Immunol. 5 2004 266 271
6. + regulatory T cells suppress NKT cell functions Cancer Res. 63 2003 4516 4520
7. W.C. Bartholomae, F.H. Rininsland, J.C. Eisenberg, B.O. Boehm, P.V. Lehmann, and M. Tary-Lehmann T cell immunity induced by live, necrotic, and apoptotic tumor cells J. Immunol. 173 2004 1012 1022
8. P. Beckhove, M. Feuerer, M. Dolenc, F. Schuetz, C. Choi, N. Sommerfeldt, J. Schwendemann, K. Ehlert, P. Altevogt, G. Bastert, V. Schirrmacher, and V. Umansky Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors J. Clin. Invest. 114 2004 67 76
9. H. Benlalam, N. Labarriere, B. Linard, L. Derre, E. Diez, M.C. Pandolfino, M. Bonneville, and F. Jotereau Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL) implications for immunotherapy Eur. J. Immunol. 31 2002 2007 2015
10. M.W. Bennett, J. O'Connell, G.C. O'Sullivan, C. Brady, D. Roche, J.K. Collins, and F. Shanahan The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma J. Immunol. 160 1998 5669 5675
11. H.T. Chao, P.H. Wang, J.Y. Tseng, C.R. Lai, S.C. Chiang, and C.C. Yuan Lymphocyte-infiltrated FIGO stage 333 IIB squamous cell carcinoma of the cervix is a prominent factor for disease-free survival Eur. J. Gynaecol. Oncol. 20 1998 136 140
12. + T lymphocytes in normal pregnancies Mol. Hum. Reprod. 8 2002 667 673
13. D.B. Chappell, and N.P. Restifo T cell-tumor cell: a fatal interaction Cancer Immunol. Immunother. 279 1998 6 10
14. D.B. Chappell, T.Z. Zaks, S.A. Rosenberg, and N.P. Restifo Human melanoma cells do not express Fas (Apo-1/CD95) ligand Cancer Res. 59 1999 59 62
15. + T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma Cancer Res. 63 2003 1555 1559
16. T.J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J.R. Conejo-Garcia, L. Zhang, M. Burow, Y. Zhu, S. Wei, I. Kryczek, B. Daniel, A. Gordon, L. Myers, A. Lackner, M.L. Disis, K.L. Knutson, L. Chen, and W. Zou Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat. Med. 10 2004 942 949
17. D. Darmochwal-Kolarz, B. Leszczynska-Gorzelak, J. Rolinski, and J. Oleszczuk The expression and concentrations of Fas/APO-1 (CD95) antigen in patients with severe pre-eclampsia J. Reprod. Immunol. 49 2001 153 164
18. + T cells become nonresponsive (anergic) following activation in the presence of costimulation J. Immunol. 163 1999 102 110
19. R. De Maria, M. Boirivant, M.G. Cifone, P. Roncaioli, M. Hahne, J. Tschopp, F. Pallone, A. Santoni, and R. Testi Functional expression of Fas and Fas ligand on human gut lamina propria T lymphocytes. A potential role for the acidic sphingomyelinase pathway in normal immunoregulation J. Clin. Invest. 97 1996 316 322
20. F. De Paola, R. Ridolfi, A. Riccobon, E. Flamini, F. Barzanti, A.M. Granato, G.L. Mordenti, L. Medri, P. Vitali, and D. Amadori Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2 Br. J. Cancer 88 2003 320 326
21. A. Diefenbach, E.R. Jensen, A.M. Jamieson, and D.H. Raulet Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity Nature 413 2001 165 171
22. H. Dong, S.E. Strome, D.R. Salomao, H. Tamura, F. Hirano, D.B. Flies, P.C. Roche, J. Lu, G. Zhu, K. Tamada, V.A. Lennon, E. Celis, and L. Chen Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat. Med. 8 2002 793 800
23. G.P. Dunn, A.T. Bruce, H. Ikeda, L.J. Old, and R.D. Schreiber Cancer immunoediting: from immunosurveillance to tumor escape Nat. Immunol. 3 2002 991 998
24. A.C. Eblen, C. Gercel-Taylor, S.T. Nakajima, and D.D. Taylor Modulation of T-cell CD3-zeta chain expression in early pregnancy Am. J. Reprod. Immunol. 47 2002 167 173
25. T.A. Ferguson, P.M. Stuart, J.M. Herndon, and T.S. Griffith Apoptosis, tolerance, and regulatory T cells - old wine, new wineskins Immunol. Rev. 193 2003 111 123
26. lck in T-cells infiltrating human renal cell carcinoma Cancer Res. 53 1993 5613 5616
27. T. Forsthuber, H.C. Yip, and P.V. Lehmann Induction of TH1 and TH2 immunity in neonatal mice Science 271 1996 1728 1730
28. M. Friberg, R. Jennings, M. Alsarraj, S. Dessureault, A. Cantor, M. Extermann, A.L. Mellor, D.H. Munn, and S.J. Antonia Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection Int. J. Cancer 101 2002 151 155
29. E.J. Fuchs, and P. Matzinger Is cancer dangerous to the immune system Semin. Immunol. 8 1996 271 280
30. Y. Gao, J.M. Herndon, H. Zhang, T.S. Griffith, and T.A. Ferguson Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosis J. Exp. Med. 188 1998 887 896
31. B.R. Gastman, Y. Atarashi, T.E. Reichert, T. Saito, L. Balkir, H. Rabinowich, and T.L. Whiteside Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes Cancer Res. 59 1999 5356 5364
32. C. Gercel-Taylor, S.M. O'Connor, G.K. Lam, and D.D. Taylor Shed membrane fragment modulation of CD3-zeta during pregnancy: link with induction of apoptosis J. Reprod. Immunol. 56 2002 29 44
33. T.S. Griffith, X. Yu, J.M. Herndon, D.R. Green, and T.A. Ferguson CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance Immunity 5 1996 7 16
34. N. Guerra, M. Guillard, E. Angevin, H. Echchakir, B. Escudier, A. Moretta, S. Chouaib, and A. Caignard Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas Blood 95 2000 2883 2889
35. A. Gunturi, R.E. Berg, and J. Forman Preferential survival of CD8 T and NK cells expressing high levels of CD94 J. Immunol. 170 2003 1737 1745
36. M. Hahne, D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L.E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J. Cerottini, and J. Tschopp Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape Science 274 1996 1363 1366
37. A.C. Halpern, and L.M. Schuchter Prognostic models in melanoma Semin. Oncol. 24 Suppl. 4 1997 S2 S7
38. P.S. Heeger, T. Forsthuber, C. Shive, E. Biekert, C. Genain, H.H. Hofstetter, A. Karulin, and P.V. Lehmann Revisiting tolerance induced by autoantigen in incomplete Freund's adjuvant J. Immunol. 164 2000 5771 5781
39. F. Hirano, K. Kaneko, H. Tamura, H. Dong, S. Wang, M. Ichikawa, C. Rietz, D.B. Flies, J.S. Lau, G. Zhu, K. Tamada, and L. Chen Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Res. 65 2005 1089 1096
40. H.N. Ho, K.H. Chao, H.F. Chen, S.U. Chen, M.Y. Wu, and Y.S. Yang Distribution of Th1 and Th2 cell populations in human peripheral and decidual T cells from normal and anembryonic pregnancies Fertil. Steril. 76 2001 797 803
41. S.M. Kang, D.B. Schneider, Z. Lin, D. Hanahan, D.A. Dichek, P.G. Stock, and S. Baekkeskov Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction Nat. Med. 3 1997 738 743
42. S.W. Kauma, T.F. Huff, N. Hayes, and A. Nilkaeo Placental Fas ligand expression is a mechanism for maternal immune tolerance to the fetus J. Clin. Endocrinol. Metab. 84 1999 2188 2194
43. L. Klein, L. Trautman, S. Psarras, S. Schnell, A. Siermann, R. Liblau, H. von Boehmer, and K. Khazaie Visualizing the course of antigen-specific CD8 and CD4 T cell responses to a growing tumor Eur. J. Immunol. 33 2003 806 814
44. V. Kolenko, Q. Wang, M.C. Riedy, H. O'Shea, J. Ritz, M.K. Cathcart, P. Rayman, R. Tubbs, M. Edinger, A. Novick, R. Bukowski, and J. Finke Tumor-induced suppression of T lymphocytes coincides with inhibition of Jak3 expression and IL-2 receptor signaling J. Immunol. 159 1997 3057 3067
45. + tumor-infiltrating lymphocyte lytic function J. Immunol. 174 2005 1830 1840
46. S. Kovats, E.K. Main, C. Librach, M. Stubblebine, S.J. Fisher, and R. DeMars A class I antigen, HLA-G, expressed in human trophoblasts Science 248 4952 1990 220 223
47. P. Lai, H. Rabinowich, P.A. Crowley-Nowick, M.C. Bell, G. Mantovani, and T.L. Whiteside Alterations in expression and function of signal transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma Clin. Cancer Res. 2 1996 161 173
48. P.P. Lee, C. Yee, P.A. Savage, L. Fong, D. Brockstedt, J.S. Weber, D. Johnson, S. Swetter, J. Thompson, P.D. Greenberg, M. Roederer, and M.M. Davis Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients Nat. Med. 5 1999 677 685
49. S. Lefebvre, M. Antoine, S. Uzan, M. McMaster, J. Dausset, E.D. Carosella, and P. Paul Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer J. Pathol. 196 2002 266 274
50. M. Lenardo, K.M. Chan, F. Hornung, H. McFarland, R. Siegel, J. Wang, and L. Zheng Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment Annu. Rev. Immunol. 17 1999 221 253
51. M. Llano, N. Lee, F. Navarro, P. Garcia, J.P. Albar, D.E. Geraghty, and M. Lopez-Botet HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer Eur. J. Immunol. 28 1998 2854 2863
52. C.B. Lopez, T.D. Rao, H. Feiner, R. Shapiro, J. Marks, and A.B. Frey Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor infiltrating lymphocytes Cell. Immunol. 190 1998 141 155
53. U. Luscher, L. Filgueira, A. Juretic, M. Zuber, N.J. Luscher, M. Heberer, and G.C. Spagnoli The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes Int. J. Cancer 57 1994 612 619
54. A.J. Marrogi, A. Munshi, A.J. Merogi, Y. Ohadike, A. El-Habashi, O.L. Marrogi, and S.M. Freeman Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma Int. J. Cancer 74 1997 492 501
55. + T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity J. Immunol. 165 2000 6047 6055
56. M. Matsuda, M. Petersson, R. Lenke, J.-L. Taupin, I. Magnusson, H. Mellstedt, P. Anderson, and R. Kiessling Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease Int. J. Cancer 61 1995 765 772
57. H. Mizoguchi, J.J. O'Shea, D. Longo, C.M. Loeffler, D.W. McVicar, and A.C. Ochoa Alteration in signal transduction molecules in T lymphocytes from tumor-bearing mice Science 258 1992 1795 1798
58. J.J. Molldrem, P.P. Lee, S. Kant, E. Wieder, W. Jiang, S. Lu, C. Wang, and M.M. Davis Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells J. Clin. Invest. 111 2003 639 647
59. D.H. Munn, M. Zhou, J.T. Attwood, I. Bondarev, S.J. Conway, B. Marshall, C. Brown, and A.L. Mellor Prevention of allogeneic fetal rejection by tryptophan catabolism Science 281 5380 1998 1191 1193
60. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer Cancer Res. 58 1998 3491 3494
61. H. Nakagomi, M. Petersson, I. Magnusson, C. Juhlin, M. Matsuda, H. Mellstedt, J.L. Taupin, E. Vivier, P. Anderson, and R. Kiessling Decreased expression of the signal-transducing ζ chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma Cancer Res. 53 1993 5610 5612
62. + T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity Cancer Res. 61 2001 5132 5136
63. M. Nakashima, K. Sonoda, and T. Watanabe Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1 Nat. Med. 5 1999 938 942
64. D.J. Nelson, S. Mukherjee, C. Bundell, S. Fisher, D. van Hagen, and B. Robinson Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL J. Immunol. 166 2001 5557 5566
65. + T cells responding to serologically defined autoantigens suppress antitumor immune responses PNAS 100 2003 10902 10906
66. J. O'Connell, M.W. Bennett, G.C. O'Sullivan, J.K. Collins, and F. Shanahan The Fas counterattack: cancer as a site of immune privilege Immunol. Today 20 1999 46 52
67. J. O'Connell, G.C. O'Sullivan, J.K. Collins, and F. Shanahan The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand J. Exp. Med. 184 1996 1075 1082
68. A.F. Ochsenbein, P. Klenerman, U. Karrer, B. Ludewig, M. Pericin, H. Hengartner, and R.M. Zinkernagel Immune surveillance against a solid tumor fails because of immunological ignorance Proc. Natl. Acad. Sci. U.S.A. 96 1999 2233 2238
69. S. Onizuka, I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody Cancer Res. 59 1999 3128 3133
70. D. Pilling, A.N. Akbar, J. Girdlestone, C.H. Orteu, N.J. Borthwick, N. Amft, D. Scheel-Toellner, C.D. Buckley, and M. Salmon Interferon-beta mediates stromal cell rescue of T cells from apoptosis Eur. J. Immunol. 29 1999 1041 1050
71. H. Rabinowich, Y. Suminami, T.E. Reichert, P. Crowley-Nowick, M. Bell, R. Edwards, and T.L. Whiteside Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma Int. J. Cancer 68 1996 276 284
72. H. Rabinowich, M. Banks, T.E. Reichert, T.F. Logan, J.M. Kirkwood, and T.L. Whiteside Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy Clin. Cancer Res. 2 1996 1263 1274
73. H. Rabinowich, T.E. Reichert, Y. Kashii, M.C. Bell, and T.L. Whiteside Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells: implications for altered expression of TcR in tumour-associated lymphocytes J. Clin. Invest. 101 1998 2579 2588
74. + tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ J. Immunol. 166 2001 6074 6083
75. + tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis J. Immunol. 167 2001 5042 5051
76. T.E. Reichert, R. Day, E. Wagner, and T.L. Whiteside Absent or low expression of the ζ chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma Cancer Res. 58 1998 5344 5347
77. T.E. Reichert, L. Strauss, E.M. Wagner, W. Gooding, and T.L. Whiteside Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma Clin. Cancer Res. 8 2002 3137 3145
78. N.P. Restifo Not so fas: re-evaluating the mechanisms of immune privilege and tumor escape Nat. Med. 6 2000 493 495
79. P. Romero, P.R. Dunbar, D. Valmori, M. Pittet, G.S. Ogg, D. Rimoldi, J.L. Chen, D. Lienard, J.C. Cerottini, and V. Cerundolo Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes J. Exp. Med. 188 1998 1641 1650
80. E. Roussel, M.C. Gingras, E.A. Grimm, and J.A. Roth High expression of adhesion molecules/activation markers with little interleukin-2, interferon-γ, and tumor necrosis factor β gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma Cancer Immunol. Immunother. 41 1995 1 9
81. R. Runic, C.J. Lockwood, Y. Ma, B. Dipasquale, and S. Guller Expression of Fas ligand by human cytotrophoblasts: implications in placentation and fetal survival J. Clin. Endocrinol. Metab. 81 1996 3119 3122
82. P. Saas, P.R. Walker, M. Hahne, A.L. Quiquerez, V. Schnuriger, G. Perrin, L. French, E.G. Van Meir, N. de Tribolet, J. Tschopp, and P.Y. Dietrich Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain J. Clin. Invest. 99 1997 1173 1178
83. M. Salmon, D. Scheel-Toellner, A.P. Huissoon, D. Pilling, N. Shamsadeen, H. Hyde, A.D. D'Angeac, P.A. Bacon, P. Emery, and A.N. Akbar Inhibition of T cell apoptosis in the rheumatoid synovium J. Clin. Invest. 99 1997 439 446
84. + T cell infiltrations within esophageal carcinomas Cancer Res. 61 2001 3932 3936
85. + T cells with a memory phenotype Cancer Res. 65 2005 632 640
86. B.C. Sheu, R.H. Lin, H.N. Ho, and S.C. Huang Down-regulation of CD25 expression on the surface of activated tumor-infiltrating lymphocytes in human cervical carcinoma Hum. Immunol. 56 1997 39 48
87. B.C. Sheu, R.H. Lin, H.C. Lien, H.N. Ho, S.M. Hsu, and S.C. Huang Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer J. Immunol. 167 2001 2972 2978
88. B.C. Sheu, S.M. Hsu, H.N. Ho, H.C. Lien, S.C. Huang, and R.H. Lin A novel role of metalloproteinase in cancer-mediated immunosuppression Cancer Res. 61 2001 237 242
89. B.C. Sheu, H.C. Lien, H.N. Ho, H.H. Lin, S.N. Chow, S.C. Huang, and S.M. Hsu Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer Cancer Res. 63 2003 6537 6542
90. + T lymphocytes in human cervical carcinoma Cancer Res. 65 2005 2921 2929
91. M. Shibakita, M. Tachibana, D.K. Dhar, T. Kotoh, S. Kinugasa, H. Kubota, R. Masunaga, and N. Nagasue Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer Clin. Cancer Res. 5 1999 2464 2469
92. + T cells: a common basis between tumor immunity and autoimmunity J. Immunol. 163 1999 5211 5218
93. K. Shiraki, N. Tsuji, T. Shioda, K.J. Isselbacher, and H. Takahashi Expression of Fas ligand in liver metastases of human colonic adenocarcinomas Proc. Natl. Acad. Sci. U.S.A. 94 1997 6420 6425
94. M.J. Smyth, D.I. Godfrey, and J.A. Trapani A fresh look at tumor immunosurveillance and immunotherapy Nat. Immunol. 2 2001 239 299
95. M.J. Smyth, K.Y.T. Thia, S.E.A. Street, E. Cretney, J.A. Trapani, M. Taniguchi, T. Kawano, S.B. Pelikan, N.Y. Crowe, and D.I. Godfrey Differential tumor surveillance by natural killer (NK) and NKT cells J. Exp. Med. 191 2000 661 668
96. + regulatory T-cell subset Immunology 112 2004 38 43
97. D.E. Speiser, R. Miranda, A. Zakarian, M.F. Bachmann, K. McKall-Faienza, B. Odermatt, D. Hanahan, R.M. Zinkernagel, and P.S. Ohashi Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy J. Exp. Med. 186 1997 645 653
98. D.E. Speiser, M.J. Pittet, D. Valmori, R. Dunbar, D. Rimoldi, D. Liénard, H.R. MacDonald, J.C. Cerottini, V. Cerundolo, and P. Romero In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes J. Exp. Med. 190 1999 775 782
99. K. Staveley-O'Carroll, E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky Induction of antigen-specific T cell anergy: an early event in the course of tumor progression PNAS 95 1998 1178 1183
100. S. Strand, W.J. Hofmann, H. Hug, M.R. Mulle, G. Otto, D. Strand, S.M. Mariani, W. Stremmel, P.H. Krammer, and P.R. Galle Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion Nat. Med. 2 1996 1361 1366
101. R.P. Sutmuller, L.M. van Duivenvoorde, A. van Elsas, T.N. Schumacher, M.E. Wildenberg, J.P. Allison, R.E. Toes, R. Offringa, and C.J. Melief Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses J. Exp. Med. 194 2001 823 832
102. M. Taniguchi, K. Seino, and T. Nakayama The NKT cell system: bridging innate and acquired immunity Nat. Immunol. 4 2003 1164 1165
103. R. Tarazona, O. DelaRosa, C. Alonso, B. Ostos, J. Espejo, J. Pena, and R. Solana Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells Mech. Ageing Dev. 121 2000 77 88
104. R. Tarazona, O. DelaRosa, J.G. Casado, J. Torre-Cisneros, J.L. Villanueva, M.D. Galiani, J. Pena, and R. Solana NK-associated receptors on CD8 T cells from treatment-naive HIV-infected individuals: defective expression of CD56 AIDS 16 2002 197 200
105. E. Tartour, S. Latour, C. Mathiot, N. Thiounn, V. Mosseri, I. Joyeux, C.D. D'Enghien, R. Lee, B. Debre, and W.H. Fridman Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function Int. J. Cancer 63 1995 205 212
106. D.D. Taylor, S.A. Sullivan, A.C. Eblen, and C. Gercel-Taylor Modulation of T-cell CD3-zeta chain expression during normal pregnancy J. Reprod. Immunol. 54 2002 15 31
107. D.D. Taylor, C. Gercel-Taylor, K.S. Lyons, J. Stanson, and T.L. Whiteside T-cell apoptosis and suppression of T-cell receptor/CD3-ζ by Fas ligand-containing membrane vesicles shed from ovarian tumors Clin. Cancer Res. 9 2003 5113 5119
108. D.D. Taylor, and C. Gercel-Taylor Alterations in T-cell signal transduction molecules associated with recurrent spontaneous pregnancy loss J. Reprod. Immunol. 63 2004 137 154
109. + T cells Nat. Immunol. 2 2001 430 435
110. C. Uyttenhove, L. Pilotte, I. Théate, V. Stroobant, D. Colau, N. Parmentier, T. Boon, and B.J. Van Den Eynde Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase Nat. Med. 9 2003 1269 1274
111. R.G. Uzzo, P. Rayman, V. Kolenko, P.E. Clark, T. Bloom, A.M. Ward, L. Molto, C. Tannenbaum, L.J. Worford, R. Bukowski, R. Tubbs, E.D. His, N.H. Bander, A.C. Novick, and J.H. Finke Mechanisms of apoptosis in T cells from patients with renal cell carcinoma Clin. Cancer Res. 5 1999 1219 1229
112. M. Varla-Leftherioti, M. Spyropoulou-Vlachou, D. Niokou, T. Keramitsoglou, A. Darlamitsou, C. Tsekoura, M. Papadimitropoulos, V. Lepage, C. Balafoutas, and C. Stavropoulos-Giokas Natural killer (NK) cell receptors' repertoire in couples with recurrent spontaneous abortions Am. J. Reprod. Immunol. 49 2003 183 191
113. S. Vesalainen, P. Lipponen, M. Talja, and K. Syrjanen Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma Eur. J. Cancer 30A 1994 1797 1803
114. P.R. Walker, P. Saas, and P.Y. Dietrich Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back J. Immunol. 158 1997 4521 4524
115. + regulatory T cells and their ligands: implications for immunotherapy Immunity 20 2004 107 118
116. T.G. Wegmann, H. Lin, L. Guilbert, and T.R. Mosmann Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon Immunol. Today 14 1993 353 356
117. E.J. Wherry, J.N. Blattman, K. Murali-Krishna, R. van der Most, and R. Ahmed Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment J. Virol. 77 2003 4911 4927
118. M. Wick, P. Dubey, H. Koeppen, C.T. Siegel, P.E. Fields, L. Chen, J.A. Bluestone, and H. Schreiber Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy J. Exp. Med. 186 1997 229 238
119. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer Cancer Res. 61 2001 4766 4772
120. H. Yagita, K. Seino, N. Kayagaki, and K. Okumura CD95 ligand in graft rejection Nature 379 1996 682
121. H.C. Yip, A.Y. Karulin, M. Tary-Lehmann, M.D. Hesse, H. Radeke, P.S. Heeger, R.P. Trezza, F.P. Heinzel, T. Forsthuber, and P.V. Lehmann Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response J. Immunol. 162 1999 3942 3949
122. M.R. Young, M.A. Wright, Y. Lozano, J.P. Mathews, J. Benefield, and M.M. Prechel Mechanisms of immune suppression in patients with head and neck cancer, influence on the immune infiltrate of the cancer Int. J. Cancer 67 1996 333 338
123. + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors J. Exp. Med. 201 2005 779 791
124. T.Z. Zaks, D.B. Chappell, S.A. Rosenberg, and N.P. Restifo Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition J. Immunol. 162 1999 3273 3279
125. L. Zhang, J.R. Conejo-Garcia, D. Katsaros, P.A. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M.N. Liebman, S.C. Rubin, and G. Coukos Intratumoral T Cells, recurrence, and survival in epithelial ovarian cancer N. Engl. J. Med. 348 2003 203 213
126. X.L. Zhang, Y. Komada, J. Chipeta, Q.S. Li, H. Inaba, E. Azuma, H. Yamamoto, and M. Sakurai Intracellular cytokine profile of T cells from children with acute lymphoblastic leukemia Cancer Immunol. Immunother. 49 2000 165 172
127. G. Zhou, Z. Lu, J.D. McCadden, H.I. Levitsky, and A.L. Marson Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression J. Exp. Med. 200 2004 1581 1592